8-KLeadership ChangesExhibits & Filings

AMGEN INC 8-K Report, Executive Changes (Dec 7, 2012)

Filed December 7, 2012For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on December 6, 2012, reporting on a significant philanthropic commitment. The company has pledged $3 million to Reed College to establish a professorship in chemical biology. This professorship is being created in honor of Dr. Roger M. Perlmutter, a former Executive Vice President of Research and Development at Amgen, who retired effective February 12, 2012. This pledge highlights Amgen's commitment to science education and its recognition of Dr. Perlmutter's contributions during his eleven years with the company. Dr. Perlmutter, an alumnus of Reed College and former chairman of its board of trustees, played a key role in Amgen's development of innovative therapies. The company views this donation as consistent with its established support for scientific education.

Key Highlights

  • 1Amgen pledged $3 million to Reed College.
  • 2The pledge will fund a new professorship in chemical biology.
  • 3The professorship is named in honor of former Amgen EVP of R&D, Roger M. Perlmutter.
  • 4Dr. Perlmutter retired from Amgen effective February 12, 2012.
  • 5Dr. Perlmutter had an eleven-year tenure at Amgen and was instrumental in developing new therapies.
  • 6Dr. Perlmutter is an alumnus of Reed College and a former chairman of its board.
  • 7The donation reflects Amgen's support for science education.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Amgen's philanthropic pledge of $3 million to Reed College to establish a professorship in chemical biology.

Roger M. Perlmutter is the former Executive Vice President of Research and Development at Amgen. He is being honored for his significant contributions to the development of new therapies during his eleven years at the company. He is also an alumnus of Reed College.

The donation aligns with Amgen's stated commitment to science education and its recognition of the importance of scientific advancement, particularly in areas related to biotechnology and medicine.

This is a philanthropic pledge and not a direct operational expense for immediate earnings impact. While it represents a financial commitment, it is viewed as an investment in science education and honoring a former executive's legacy, rather than a core business expense affecting quarterly results.